B-Raf inhibitor 1 dihydrochloride is primarily used in cancer research and treatment, specifically targeting cancers driven by mutations in the BRAF gene. It works by inhibiting the activity of the B-Raf protein, which is often mutated in various cancers, including melanoma, colorectal cancer, and thyroid cancer. By blocking this protein, the inhibitor helps to slow down or stop the growth of cancer cells. It is commonly employed in preclinical studies to understand the mechanisms of BRAF-driven cancers and to develop targeted therapies. Additionally, it is used in combination with other drugs to enhance efficacy and overcome resistance in cancer treatment.